Key Highlights

  • In quarterly results published November 9, 2026, Roivant Sciences (NASDAQ:ROIV) booked USD 31.0 million of net product sales for LISRAYA during its first five US weeks.
  • Quarter-to-September 30 total Revenue came to USD 35.1 million, with USD 4.2 million tied to license and milestone payments.
  • Cash, equivalents and marketable securities stood near USD 4.2 billion, and 2.1 million shares were repurchased for approximately USD 72.5 million in the period.
  • Pipeline news featured a registrational-stage rheumatoid arthritis success for IMVT-1402 and positive Phase 3 uveitis findings for brepocitinib, marketed as LISRAYA.

Early Commercial Performance

LISRAYA is the commercial name of brepocitinib, which the FDA cleared in August 2026 with US availability starting that same month. Over five weeks the product produced USD 31.0 million in net sales for Roivant Sciences (NASDAQ:ROIV), an encouraging result for a fresh specialty medicine during a partial opening quarter. Spending on the launch pushed SG&A up to USD 154.1 million (USD 143.1 million before), whereas R&D fell to USD 145.7 million from USD 164.6 million. Continuing operations posted a loss of USD 153.0 million, or USD 0.29 a share, and the net loss attributable to Roivant amounted to USD 191.6 million. That figure carried USD 95.9 million of payouts to holders of awards at its Genevant unit, equal to USD 0.13 per share. Stripping out those items leaves an adjusted continuing-operations loss of USD 133.4 million. Results beat market expectations, and the stock climbed following the release.

Pipeline Readouts Across Immunology and Lung Disease

Immunovant, a majority-owned Roivant unit, said a 600 milligram dose of IMVT-1402, an FcRn blocker, hit its main goal in a potentially registrational trial for hard-to-treat rheumatoid arthritis. By week 28, 92.5% of patients on that dose reached an ACR20 response, compared with 75.6% given placebo. The 300 milligram level failed to distinguish itself from placebo, and no serious adverse events appeared during that span. Talks with the FDA are slated for later this year. In two Phase 3 studies for non-infectious uveitis, brepocitinib hit its main target and all major secondary aims, and median time before treatment failure ran past 48 weeks, against about 12 weeks with placebo. A supplemental filing to widen the label is targeted for the first half of 2027. Mosliciguat, belonging to the Pulmovant unit, reduced pulmonary vascular resistance by 56.3% relative to placebo in a Phase 2 study for pulmonary hypertension tied to lung disease, and a Phase 3 trial has launched.

Balance Sheet Strength and Appeal Exposure

Roivant Sciences (NASDAQ:ROIV) ranks among the sturdiest balance sheets in the mid-cap biotech space, with about USD 4.2 billion in cash and securities. The total includes USD 950 million received in July under a lipid nanoparticle Patent settlement that could reach USD 2.25 billion, with another USD 1.3 billion contingent on an appeal argued on November 5, 2026. Management asserts that the cash runway runs through to profitability. Hazards include how quickly LISRAYA sales progress after initial stocking, rivalry in autoimmune markets, the uneven dose response seen in the IMVT-1402 trial and the appeal outcome. Immunovant has additionally halted a cutaneous lupus study. Observers will monitor fourth-quarter LISRAYA sales, FDA guidance on IMVT-1402 in rheumatoid arthritis, the appellate ruling and the investor day scheduled for December 9, 2026.

Where Things Stand

Roivant Sciences (NASDAQ:ROIV) generated USD 31.0 million of LISRAYA sales within five weeks, a promising debut for its flagship launch, while pipeline data in rheumatoid arthritis and uveitis came in positive and cash stood near USD 4.2 billion. The net loss was USD 191.6 million, partly due to one-off distributions. Another USD 1.3 billion of settlement proceeds hinges on an appeal. Next checkpoints are the fourth-quarter LISRAYA tally and the investor gathering on December 9.